IBBvsETF 2ETF Comparison
VS
Choose a second ETF to run a side-by-side ETF comparison with IBB, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
IBB performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 07/27/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | IBB ETF 2 | -0.75%– | +11.49%– | +11.67%– | +40.98%– | +48.54%– | +17.67%– |
| Flows | IBB ETF 2 | +$247M– | +$298M– | +$98M– | +$1.48B– | -$917M– | -$1.71B– |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | IBB ETF 2 | +22.57%– | +20.32%– | +20.42%– | +22.33%– |
| Max drawdown | IBB ETF 2 | -5.94%– | -9.61%– | -24.82%– | -39.75%– |
| Max drawdown duration | IBB ETF 2 | 20d– | 151d– | 377d– | 1611d– |
Trading data
IBB | ETF 2 | |
Last sale 7/28/2026 at 1:30 PM | $190.47 | – |
| Previous close 07/27/2026 | $188.33 | – |
| Consolidated volume 07/27/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Replication quality
Data as of June 30, 2026
1-year trailing difference
Create an account to view replication metrics
Join for free
IBB | ETF 2 | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
Advertisement
Main metrics
Last update 7/28/2026 at 1:30 PM
Live
Closed
IBB | ETF 2 | |
|---|---|---|
| Last price | $190.47 | – |
| 1D performance | +1.14% | – |
| AuM | $9.36 B | – |
| E/R | 0.44% | – |
Characteristics
IBB | ETF 2 | |
|---|---|---|
| Management strategy | Passive | – |
| Provider | iShares | – |
| Benchmark | ICE Biotechnology Index | – |
| N° of holdings | 242 | – |
| Asset class | Equities | – |
| Trailing 12m distribution yield | Join | Join |
| Inception date | February 5, 2001 | – |
| ESG | No | – |
Advertisement
Exposure
Countries
IBB
USA
86.15%
Other
13.85%
ETF 2
Sectors
IBB
Healthcare
99.89%
Other
0.11%
ETF 2
Advertisement
Diversification
IBB
Total weight of top 15 holdings out of 15
53.71%
ETF 2
–
Top 15 holdings
Data as of June 30, 2026
IBB
Vertex Pharmaceuticals, Inc.
8.07%
Amgen, Inc.
7.82%
Gilead Sciences, Inc.
6.83%
Regeneron Pharmaceuticals, Inc.
4.90%
argenx SE
3.75%
Alnylam Pharmaceuticals, Inc.
3.12%
Natera, Inc.
2.89%
Revolution Medicines, Inc.
2.78%
Biogen, Inc.
2.46%
Illumina, Inc.
2.07%
Moderna, Inc.
1.98%
Insmed, Inc.
1.78%
BeOne Medicines Ltd.
1.77%
Incyte Corp.
1.75%
United Therapeutics Corp.
1.73%
ETF 2
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
Advertisement
Latest news about IBB
Small-Cap Biotech ETFs: High-Risk, High-Reward Opportunities
September 18, 2025
IBB
Are Biotechnology ETFs In the Midst of a Comeback?
August 20, 2025
IBB
Investing in the Aging Population: A Look at Bonds and Pharma ETFs
March 27, 2023
IBB
Health is Wealth: A look at the Healthcare Sector
January 24, 2023
IBB
Advertisement
Biotech ETFs – Investing in Health Innovation
July 21, 2022
IBB
Biotech ETFs – Investing in Health Innovation
July 21, 2022
IBB
Advertisement
